Both investor forums were a great success, with notable attendees including Infidar Investment Advisory, BB Bellevue Asset Management, Centrum Bank, Taylor Wessing, BVMW and UBS Global Asset Management.
NeoStem’s CEO and Chairman Robin Smith updated investors on the company’s adult stem cell operations in the U.S., network of adult stem cell therapeutic providers in China, and recent acquisition of a 51% interest in a profitable Chinese generic pharmaceutical manufacturing company.
The company is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.
NeoStem was recently given an initial "outperform" rating from US equity research firm Cowen, based on recent acquisitions and tie ups strengthening the company's adult stem cell banking capabilities.
Ken Aldrich, Chairman and Co-Founder of International Stem Cell Corporation also had plenty to introduce to European audiences. The California-based biotechnology company is focused on the therapeutic applications of human stem cells and the development and commercialization of cell-based research and cosmetic products.
The company’s core technology, Parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes. This technique avoids ethical issues associated with the use or destruction of viable human embryos and can be a source of therapeutic cells that minimize or eliminate immune rejection after transplantation into the patient.